Project Optimus – A Reform in the Dose Optimization and Selection in Oncology Drug Development
Project Optimus is an initiative proposed by the US Food and Drug Administration's Oncology Centre of Excellence (OCE) to provide new guidance for dose optimization early in oncology drug development.
In this white paper, Dr Laurie Smaldone Alsup, SVP Regulatory Science at NDA, explores the goals of Project Optimus and how it can impact time to approval, ultimately aiming to improve the oncology drug development process, and ensure optimal dose selection before approval.
Download
Fill out the form on the right to download this content.
Contact us
Your drug development needs are unique
Contact us to learn how our experts can support you to meet all regulatory, quality and safety requirements and ensure the best path to approval.
Let's Bring Medicines to the World